BioPharma Resources

Investigational drug · Phase 3

Tersolisib

Also called: LY4064809, STX-478

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Neoplasms, Neoplasm Metastasis, Breast Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

5

Any phase or sponsor naming "Tersolisib"

First trial start

2023

Apr 17, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tersolisib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Breast Neoplasms
  • Neoplasm Metastasis
  • Breast Cancer
  • Solid Tumors, Adult

Approved drugs for the same conditions: Breast cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Tersolisib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for Breast Neoplasms

  • AL8326Phase 34 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • NuvastaticPhase 32 trials

    Natureceuticals Sdn Bhd · Fatigue, Colon Cancer, Breast Neoplasms

  • HLX11Phase 31 trial

    Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

  • Zelenectide pevedotinBT8009Phase 25 trials

    BicycleTx Limited · Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors

  • AL58805Phase 22 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • endoxifenPhase 22 trials

    Atossa Therapeutics, Inc. · Precocious Puberty, Gonadotropin-dependent, Breast Neoplasms, Invasive Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.